1. Noguchi E, Yamanaka T, Yamamoto N, Chung C-F, Lu Y-S, Chang D-Y, et al. Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. Journal of Clinical Oncology. 2023;41:LBA1068-LBA. Here, ERBB2 is linked to breast cancer.